ARO-APOC3
- Generic Name
- ARO-APOC3
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Study of ARO-APOC3 in Adults With Dyslipidemia
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 418
- Registration Number
- NCT05413135
- Locations
- ๐บ๐ธ
Preventive Cardiology Inc., Boca Raton, Florida, United States
๐บ๐ธA&R Research Group, Pembroke Pines, Florida, United States
๐บ๐ธAlta Pharmaceutical Research Center, Dunwoody, Georgia, United States
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04998201
- Locations
- ๐บ๐ธ
Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States
๐บ๐ธPreventive Cardiology Inc., Boca Raton, Florida, United States
๐บ๐ธA & R Research Group, Pembroke Pines, Florida, United States
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04720534
- Locations
- ๐บ๐ธ
Pioneer Research Solutions, Inc., Houston, Texas, United States
๐บ๐ธClinical Research of South Nevada, Las Vegas, Nevada, United States
๐บ๐ธAppleMed Research Group, Miami, Florida, United States
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03783377
- Locations
- ๐ฆ๐บ
Linear Clinical Research, Perth, Western Australia, Australia
๐ฆ๐บRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.